Simple Summary Prostate cancer can develop under hormone treatment and chemotherapy
from a castration-sensitive towards a castration-resistant into a drug resistant-tumor. The …

Androgen receptor (AR) signaling is a critical pathway for prostate cancer cells, and
androgen-deprivation therapy (ADT) remains the principal treatment for patients with locally …

Androgen receptor (AR) is the main target for prostate cancer therapy. Clinical approaches
for AR inactivation include chemical castration, inhibition of androgen synthesis and AR …

Prostate cancer (PCa) is the most widely diagnosed male cancer in the Western World and
while low-and intermediate-risk PCa patients have a variety of treatment options, metastatic …

The role of the androgen receptor (AR) signaling axis in the progression of prostate cancer
is a cornerstone to our understanding of the molecular mechanisms causing castration …

Around 80–90% of prostate cancer (PCa) cases are dependent on androgens at initial
diagnosis; hence, androgen ablation therapy directed toward a reduction in serum …

Activation of the androgen receptor (AR) and AR-driven transcriptional programs is central to
the pathophysiology of prostate cancer. Despite successful translational efforts in targeting …

The androgen receptor is a transcription factor and validated therapeutic target for prostate
cancer. Androgen deprivation therapy remains the gold standard treatment, but it is not …

Simple Summary Castration-resistant prostate cancer (CRPC) remains a significant medical
challenge, even with recent advancements in diagnosis and treatment. To improve patient …

The androgen receptor (AR) is the main therapeutic target in advanced prostate cancer,
because it regulates the growth and progression of prostate cancer cells. Patients may …